Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now full pipeline small index

Stage I Uterine Corpus Cancer: full-pipeline trial registry

1 of 5 indexed Stage I Uterine Corpus Cancer trials are currently recruiting.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Stage I Uterine Corpus Cancer: 5 US clinical trials tracked, 1 recruiting.

Stage I Uterine Corpus Cancer is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Gynecologic Oncology Group, running 4 of these trials.

Enrollment posture brief

Registry condition stage-i-uterine-corpus-cancer

OPEN 1 | RECR 20% | LATE 1 | EARLY 1 | RANK #3391 | SPON 4

Volume-matched condition peers

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Stage I Uterine Corpus C (th…20%
Open-enrollment share among volume-matched conditions near Stage I Uterine Corpus Cancer

Stage I Uterine Corpus Cancer lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Stage I Uterine Corpus Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Stage I Uterine Corpus Cancer is recruiting below its size-band peers.

    1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Stage I Uterine Corpus Cancer research.

    Gynecologic Oncology Group accounts for 4 of 5 trials (80%). 2 distinct sponsors appear on at least one study for this condition label.

  3. Typical Stage I Uterine Corpus Cancer enrolment sits around 243 participants.

    Median target enrolment is 243 among the 5 trials that report a genuine target (sentinel values excluded). 1 of those (20%) plan for fewer than 100 participants.

  4. Stage I Uterine Corpus Cancer research leans observational.

    2 interventional and 3 observational studies make up this index (40% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 21Phase 31

Phase Distribution

PhaseTrial count
Phase 2 1
Phase 3 1

Top Sponsors

Gynecologic Oncology Group 4 trials
University of Utah 1 trials

Named interventions

Most-linked intervention names on Stage I Uterine Corpus Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Laboratory Biomarker Analysis Other
3 trials
Study of Socioeconomic and Demographic Variables Other
2 trials
Microarray Analysis Genetic
1 trials
Immunohistochemistry Staining Method Other
1 trials
Medroxyprogesterone Drug
1 trials
Short course vaginal cuff brachytherapy Radiation
1 trials
Vaginal Cuff Brachytherapy Radiation
1 trials
Diagnostic Laboratory Biomarker Analysis Other
1 trials

US sites by state

Facility locations filed on Stage I Uterine Corpus Cancer trials. A trial with sites in several states counts in each.

Pennsylvania 4 trials
Utah 1 trials
Texas 1 trials
Illinois 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Stage I Uterine Corpus Cancer page

5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage I Uterine Corpus Cancer condition card totals 5 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.